(Q34915389)

English

Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Phase II trial of ixabepilone administered daily for five days in children and young adults with refractory solid tumors: a report from the children's oncology group (English)

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

phase II clinical trial

0 references

1 reference

based on heuristic

inferred from title

7

object named as

Susan M Blaney

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

author name string

Shana Jacobs

1

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Elizabeth Fox

2

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Mark Krailo

3

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Gwen Hartley

4

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Fariba Navid

5

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Leonard Wexler

6

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Anne Goodwin

8

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Wendy Goodspeed

9

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Frank M Balis

10

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Peter C Adamson

11

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Brigitte C Widemann

12

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

language of work or name

0 references

publication date

12 January 2010

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Clinical Cancer Research

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

16

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

750-754

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Clinical development of ixabepilone and other epothilones in patients with advanced solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086796

8 July 2018

Phase I trial and pharmacokinetic study of ixabepilone administered daily for 5 days in children and adolescents with refractory solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086796

8 July 2018

In vivo evaluation of ixabepilone (BMS247550), a novel epothilone B derivative, against pediatric cancer models

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086796

8 July 2018

Epothilones: mechanism of action and biologic activity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086796

8 July 2018

Phase I trial and pharmacokinetic study of BMS-247550, an epothilone B analog, administered intravenously on a daily schedule for five days.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086796

8 July 2018

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086796

8 July 2018

Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: a collaborative Pediatric Oncology Branch, National Cancer Institute and Children's Cancer Group trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086796

8 July 2018

Phase I trial of docetaxel administered as a 1-hour infusion in children with refractory solid tumors: a collaborative pediatric branch, National Cancer Institute and Children's Cancer Group trial

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086796

8 July 2018

Phase I trial of paclitaxel in children with refractory solid tumors: a Pediatric Oncology Group Study.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086796

8 July 2018

The pediatric preclinical testing program: description of models and early testing results.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086796

26 October 2018

Phase II investigation of docetaxel in pediatric patients with recurrent solid tumors: a report from the Children's Oncology Group.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086796

26 October 2018

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in metastatic and locally advanced breast cancer

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086796

26 October 2018

Phase I clinical and pharmacokinetic study of BMS-247550, a novel derivative of epothilone B, in solid tumors

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086796

26 October 2018

BMS-247550: a novel epothilone analog with a mode of action similar to paclitaxel but possessing superior antitumor efficacy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3086796

26 October 2018

Paclitaxel for the treatment of progressive or recurrent childhood brain tumors: a pediatric oncology phase II study

1 reference

https://pubmed.ncbi.nlm.nih.gov/20068084

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II Trial of Ixabepilone, an Epothilone B Analog, in Patients With Metastatic Breast Cancer Previously Untreated With Taxanes

1 reference

https://pubmed.ncbi.nlm.nih.gov/20068084

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy

1 reference

https://pubmed.ncbi.nlm.nih.gov/20068084

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase II Clinical Trial of Ixabepilone (BMS-247550), an Epothilone B Analog, in Patients With Taxane-Resistant Metastatic Breast Cancer

1 reference

https://pubmed.ncbi.nlm.nih.gov/20068084

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Phase I clinical study of the novel epothilone B analogue BMS-310705 given on a weekly schedule

1 reference

https://pubmed.ncbi.nlm.nih.gov/20068084

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1158/1078-0432.CCR-09-1906

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

5 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34915389&oldid=1642599165"